A new wave of research shines a promising light on cannabis and its compounds, suggesting their potential to curb the spread and severity of COVID-19 infections. Furthermore, they could play a crucial role in managing long COVID symptoms, including mental health challenges and appetite loss. Researchers at Dalhousie University in Canada meticulously reviewed existing scientific literature, unearthing intriguing findings about marijuana as a preventive and therapeutic aid, as detailed in the Journal of Clinical Medicine.
Cannabis compounds, particularly cannabinoids, are highlighted for their ability to block the virus's entry, reduce oxidative stress, and soothe the intense immune response known as the "cytokine storm," which is a hallmark of early COVID-19 infections. Following the battle with the virus, cannabinoids have been observed to ease post-COVID conditions like depression, anxiety, PTSD, insomnia, pain, and decreased appetite, showcasing a beacon of hope for long COVID sufferers.
The research underscores a concerted effort to bridge the knowledge gap regarding the endocannabinoid system (ECS) and its modulation in both the early and post-infection stages of COVID-19. While cannabis has been considered for treatment during the acute phase, this study broadens the perspective, suggesting a potential role in prevention and long-term recovery.
Comments (0)